Fairscale Capital’s Citius Pharmaceuticals CTXR Stock Holding History

Fairscale Capital’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38	Hold	42	–	–	﹤0.01%	436
2025 Q4	$33	Hold	42	–	–	﹤0.01%	426
2025 Q3	$52	Hold	42	–	–	﹤0.01%	442
2025 Q2	$58	Hold	42	–	–	﹤0.01%	439
2025 Q1	$63	Sell	42 -324	-89%	-$775	﹤0.01%	350
2024 Q4	$1.46K	Hold	366	–	–	﹤0.01%	317
2024 Q3	$4.58K	Hold	366	–	–	﹤0.01%	274
2024 Q2	$7.78K	Buy	+366	New	+$6.56K	0.01%	267

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Fairscale Capital's CTXR Position: Q1 2026 in Review

Fairscale Capital held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 42 shares worth $38. The position accounts for ﹤0.01% of the portfolio, ranked #436.

Fairscale Capital first reported a position in CTXR in Q2 2024 and has held it in 8 quarters since. The position peaked at $7.78K in Q2 2024. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

Fairscale Capital held 42 shares of Citius Pharmaceuticals worth $38 as of Q1 2026.
Fairscale Capital left its Citius Pharmaceuticals share count unchanged in Q1 2026.
Citius Pharmaceuticals made up ﹤0.01% of Fairscale Capital's portfolio in Q1 2026, its #436 holding.
Fairscale Capital first reported a position in Citius Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Fairscale Capital's Citius Pharmaceuticals position peaked at $7.78K in Q2 2024.
38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Fairscale Capital's 13F filing for Q1 2026, filed 11 May 2026.